AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 DEC 27 - (NewsRx.com & NewsRx.net) -- Bedford Laboratories, a division of Ben Venue Laboratories, Inc., began shipping pamidronate disodium for injection December 3, 2001. Bedford Laboratories' drug is the first generic version approved and will enjoy 180 days exclusivity under the Waxman-Hatch Act.
The product is equivalent to Aredia from Novartis Pharmaceuticals, a bone-resorption inhibitor indicated for the treatment of hypercalcemia associated with malignancy, for Paget disease, for osteolytic bone metastases of breast cancer, and for osteolytic lesions of multiple myeloma. Aredia had worldwide sales of over $663 million in 2000, according to Med Ad News, a ...
Source: HighBeam Research, Bedford Labs Begins Shipping Pamidronate Disodium For...